마우스 세포에서 psoralen 계열 화합물의 항염증 및 멜라닌 생성 효과 규명

Abstract

In this study, we investigated the biological activity according to the structural difference of Psoralen derivatives in RAW 264.7 cells and B16F10 melanoma cells. We also investigated the mechanism of Xanthotoxol in RAW 264.7 cells and of Bergapten in B16F10 melanoma cells. The RAW 264.7 cells were treated with Xanthotoxol (62.5, 125, 250 and 500 μM) respectively to observe its effects. As a result, Xanthotoxol significantly decreased on the production of inflammatory mediators (NO, PGE2) and pro-inflammatory cytokines (IL-6, IL-1β, TNF-α). Western blot results showed that the protein expression of iNOS and COX-2 were decreased by Xanthotoxol. Xanthotoxol reduced the phosphorylation of the mitogen activated protein kinase (MAPK). Xanthotoxol also reduced the phosphorylarion of IκBα in the nuclear factor kappa B (NF-κB) pathway. These results suggest that Xanthotoxol is a potential treatment for inflammation. The B16F10 melanoma cells were treated with Bergapten (6.25, 12.5, 25 and 50 μM) respectively to observe its effects. As a result, Bergapten increased melanin contents and tyrosinase activity in B16F10 cells. Western blot results showed that the protein expression of Tyrosinase, TRP-1, TRP-2 and (microphthalmia associated transcription factor) MITF were increased by Bergapten. Bergapten increased the phosphorylation of glycogen synthase kinase 3β (GSK3β) at Ser 9 and the expression of β-catenin. Bergapten increased the phosphorylation of porotein kinase A (PKA) and MAPKs. On the other hand, Bergapten increased the expression of MITF by inhibiting the phosphorylation of AKT. These results suggest that Bergapten is a potential treatment for hypopigmentation.